EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study

EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study

Abstract Background LUAD patients with EGFR exon 20 insertions (ex20ins) have a poorer prognosis than those with EGFR 19del or L858R mutations. The FAVOUR study showed high-dose furmonertinib’s efficacy in ex20ins patients. However, more real-world data are needed to validate these findings. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Sen Yang, Yang Liu, Jiuzhou Zhao, Zhen He, Haiyang Chen, Shuxiang Ma, Yingxi Wu, Yufeng Wu, Lili Wang, Cuicui Zhang, Qiming Wang
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
EGFR
Furmonertinib
Lung adenocarcinoma
EGFR ex20ins
Online Access:https://doi.org/10.1186/s12885-025-14313-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14313-7

Similar Items